Walleye Trading LLC Fibrogen Inc Call Options Transaction History

Walleye Trading LLC

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $109,809 - $908,019	-44,100 Reduced 62.29%	26,700 $72,000
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $1.13 Million - $1.78 Million	70,800 New	70,800 $1.32 Million
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $635,232 - $1.66 Million	62,400 Added 6240.0%	63,400 $648,000
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $18,570 - $35,680	1,000 New	1,000 $27,000
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $195,300 - $351,036	-6,300 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $163,196 - $215,468	4,400 Added 231.58%	6,300 $234,000
Q3 2020 Nov 16, 2020	BUY	$40.47 - $45.5 $40,470 - $45,500	1,000 Added 111.11%	1,900 $78,000
Q2 2020 Aug 14, 2020	SELL	$32.57 - $42.83 $153,079 - $201,301	-4,700 Reduced 83.93%	900 $36,000
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $179,410 - $353,892	-7,700 Reduced 57.89%	5,600 $195,000
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $345,800 - $480,600	10,000 Added 303.03%	13,300 $570,000
Q3 2019 Nov 14, 2019	SELL	$36.98 - $48.45 $173,805 - $227,715	-4,700 Reduced 58.75%	3,300 $122,000
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $281,040 - $444,240	8,000 New	8,000 $361,000
Q4 2018 Feb 14, 2019	SELL	$37.97 - $60.16 $326,542 - $517,375	-8,600 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $270,240 - $322,800	4,800 Added 126.32%	8,600 $522,000
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $224,500 - $324,750	-5,000 Reduced 56.82%	3,800 $238,000
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $399,080 - $542,520	8,800 New	8,800 $407,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $46.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.